A number of other research firms have also issued reports on SGEN. TheStreet lowered shares of Seagen from a c- rating to a d+ rating in a research report on Friday, November 3rd. Truist Financial reaffirmed a hold rating and set a $229.00 target price on shares of Seagen in a research note on Wednesday, October 18th. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Hold and a consensus price target of $197.69.
Seagen Stock Performance
Hedge Funds Weigh In On Seagen
A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Seagen by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 12,279,156 shares of the biotechnology company’s stock valued at $1,768,813,000 after acquiring an additional 139,117 shares during the period. BlackRock Inc. grew its holdings in Seagen by 7.6% during the 2nd quarter. BlackRock Inc. now owns 12,041,819 shares of the biotechnology company’s stock valued at $2,317,568,000 after purchasing an additional 850,697 shares in the last quarter. Primecap Management Co. CA grew its holdings in Seagen by 3.7% during the 3rd quarter. Primecap Management Co. CA now owns 6,261,798 shares of the biotechnology company’s stock valued at $1,328,440,000 after purchasing an additional 222,990 shares in the last quarter. State Street Corp grew its holdings in Seagen by 0.7% during the 1st quarter. State Street Corp now owns 3,525,411 shares of the biotechnology company’s stock valued at $507,835,000 after purchasing an additional 24,853 shares in the last quarter. Finally, Norges Bank acquired a new stake in Seagen during the 4th quarter valued at $281,065,000. Hedge funds and other institutional investors own 84.26% of the company’s stock.
Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
- Five stocks we like better than Seagen
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- 3 attractive stocks that insiders are buying
- Why Are Stock Sectors Important to Successful Investing?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Blockchain Stocks Step by Step
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.